Some recent reports have demonstrated that PTEN activation contributes to tumour inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in vitro, in vivo and in the clinical setting (Crowder et al, 2004; Nagata et al, 2004; Pandolfi, 2004). Here, PTEN is linked to neoplasm.